News | April 01, 2013

Lantheus Announces Molybdenum-99 Supply Contract with Institute for Radioelements

Under the terms of the five-year agreement, IRE will provide an increasing supply of Mo-99

April 1, 2013  Lantheus Medical Imaging Inc. announced a new supply contract with the Belgium-based Institute for Radioelements (IRE) to receive a supply of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), for use in its TechneLite (Technetium Tc 99m Generator) generators.

Under the terms of the five-year agreement, IRE will provide an increasing supply of Mo-99 through Dec. 31, 2017. The new agreement also provides for the transition to Mo-99 sourced from Low-Enriched Uranium (LEU) upon IRE’s completion of its ongoing conversion program to modify its facilities and processes in accordance with Belgian nuclear security commitments.

“We are focused on enhancing our balanced and diverse supply chain for this important medical isotope to ensure that we consistently meet the needs of customers and their patients,” said Jeff Bailey, president and CEO of Lantheus Medical Imaging. “Over the course of this agreement, IRE will also help support our strategic initiatives related to supply chain stability and the conversion to 100 percent LEU-derived Mo-99.”

Lantheus has developed a globally diversified and balanced Mo-99 supply chain for the procurement of Mo-99. The company receives Mo-99 from four of the five major processors and seven of the eight associated reactors. 

For more information: www.lantheus.com

Related Content

ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers| August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging| July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers| May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers| April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers| April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers| April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| April 05, 2017
April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging| March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers| March 01, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging| January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Overlay Init